News
Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
3d
Zacks.com on MSNGSK's Specialty Medicines Unit on a Strong Footing: Here's WhyGSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
4d
MedPage Today on MSNManaging Weight in COPDDietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.
GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has ...
GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...
3d
Irish Examiner on MSNMerck closing on $10bn deal for respiratory drugmaker VeronaMerck is closing in on a $10bn (€8.5bn) deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported.
Merck & Co. agreed to buy UK biotech Verona Pharma Plc for about $10 billion to offset the looming loss of patent protection on its top-selling cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results